HUP0203484A2 - Galantamint és édesítőszert tartalmazó orális oldat és eljárás az előállítására - Google Patents
Galantamint és édesítőszert tartalmazó orális oldat és eljárás az előállításáraInfo
- Publication number
- HUP0203484A2 HUP0203484A2 HU0203484A HUP0203484A HUP0203484A2 HU P0203484 A2 HUP0203484 A2 HU P0203484A2 HU 0203484 A HU0203484 A HU 0203484A HU P0203484 A HUP0203484 A HU P0203484A HU P0203484 A2 HUP0203484 A2 HU P0203484A2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutically acceptable
- disease
- oral solution
- disorders
- alzheimer
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 6
- 235000003599 food sweetener Nutrition 0.000 title abstract 3
- 229960003980 galantamine Drugs 0.000 title abstract 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 3
- 229940100688 oral solution Drugs 0.000 title abstract 3
- 239000003765 sweetening agent Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000001375 Facial Neuralgia Diseases 0.000 abstract 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 206010028424 Myasthenic syndrome Diseases 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 208000037280 Trisomy Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 208000012790 cranial neuralgia Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A találmány tárgya olyan orális oldat galantamin, vagy gyógyászatilagelfogadható sója - tartalommal, amely 0,005-3 vegyes% mennyiségbenédesítőszert tartalmaz. Ezt az oldatot a találmány értelmében úgyállítják elő, hogy - galantamint vagy valamelyik gyógyászatilagelfogadható sóját, egy intenzív édesítőszert, adott esetben továbbigyógyászatilag elfogadható segédanyagokat és a folyékonyhordozóanyagot összekevernek teljes feloldódásig; - adott esetben akapott oldat pH-értékét 4 és 8 közé beállítják; - a kapott oldatot akívánt végtérfogatra tisztított vízzel hígítják. A találmány szerintiorális oldat felhasználható olyan gyógyászati készítményekelőállítására, amelyek a következő megbetegedésektől szenvedő betegekkezelésére alkalmasak: Alzheimer-kór és rokon elmebajok, vaszkuláriselmebaj, vegyes (Alzheimer- és vaszkuláris) elmebaj, enyhe kognitívelégtelenség (angolszász rövidítéssel: MCI), Lewy-féle megbetegedés(angolszász rövidítéssel: LBD), Parkinson-kór, skizofrénia, ízületigyulladásos rendellenességek, krónikus fáradtsági szindróma, faciálisneuralgia, figyelemhiánnyal kapcsolatos rendellenességek, obstruktivalvási légzéselakadás, időzónaváltoztatásból adódó panaszok,alkoholfüggőség, nikotinfüggőség, mánia, trisomia, terhességiizomgyengeség (myasthenia gravis) és Eaton-Lambert-szimptóma. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203512 | 1999-10-26 | ||
| PCT/EP2000/010203 WO2001030318A1 (en) | 1999-10-26 | 2000-10-16 | Oral solution containing galanthamine and a sweetening agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203484A2 true HUP0203484A2 (hu) | 2003-02-28 |
| HUP0203484A3 HUP0203484A3 (en) | 2004-12-28 |
Family
ID=8240778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203484A HUP0203484A3 (en) | 1999-10-26 | 2000-10-16 | Oral solution containing galanthamine and a sweetening agent and process for their preparation |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1237539B1 (hu) |
| JP (1) | JP2003512415A (hu) |
| KR (1) | KR100502391B1 (hu) |
| CN (1) | CN1200691C (hu) |
| AR (1) | AR026243A1 (hu) |
| AT (1) | ATE306904T1 (hu) |
| AU (1) | AU780826C (hu) |
| BG (1) | BG65792B1 (hu) |
| BR (1) | BR0015025A (hu) |
| CA (1) | CA2388830C (hu) |
| CZ (1) | CZ301996B6 (hu) |
| DE (1) | DE60023341T2 (hu) |
| DK (1) | DK1237539T3 (hu) |
| EA (1) | EA005683B1 (hu) |
| EE (1) | EE05230B1 (hu) |
| ES (1) | ES2250211T3 (hu) |
| HK (1) | HK1049619A1 (hu) |
| HR (1) | HRP20020332B1 (hu) |
| HU (1) | HUP0203484A3 (hu) |
| IL (2) | IL149310A0 (hu) |
| IS (1) | IS2628B (hu) |
| MX (1) | MXPA02004149A (hu) |
| NO (1) | NO332096B1 (hu) |
| PL (1) | PL201694B1 (hu) |
| SI (1) | SI1237539T1 (hu) |
| SK (1) | SK285643B6 (hu) |
| TW (1) | TW592725B (hu) |
| UA (1) | UA76095C2 (hu) |
| WO (1) | WO2001030318A1 (hu) |
| ZA (1) | ZA200203313B (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| CA2535613A1 (en) | 2003-08-13 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Treatment of sleep disorders with cholinesterase inhibitors |
| WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
| US8709521B2 (en) * | 2007-05-22 | 2014-04-29 | The Coca-Cola Company | Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles |
| US9708366B2 (en) * | 2011-01-27 | 2017-07-18 | Neuren Pharmaceuticals Ltd. | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate |
| US20140107130A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals, LLC | Oral Solution Formulations of Aripiprazole |
| JP6457582B2 (ja) * | 2017-04-14 | 2019-01-23 | エルメッド エーザイ株式会社 | ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| JPH10273435A (ja) * | 1997-01-29 | 1998-10-13 | Fujisawa Pharmaceut Co Ltd | 内服用液剤 |
-
2000
- 2000-10-16 BR BR0015025-8A patent/BR0015025A/pt not_active Application Discontinuation
- 2000-10-16 EE EEP200200213A patent/EE05230B1/xx unknown
- 2000-10-16 JP JP2001532738A patent/JP2003512415A/ja active Pending
- 2000-10-16 ES ES00975872T patent/ES2250211T3/es not_active Expired - Lifetime
- 2000-10-16 TW TW089121526A patent/TW592725B/zh not_active IP Right Cessation
- 2000-10-16 SK SK530-2002A patent/SK285643B6/sk not_active IP Right Cessation
- 2000-10-16 EA EA200200486A patent/EA005683B1/ru not_active IP Right Cessation
- 2000-10-16 IL IL14931000A patent/IL149310A0/xx active IP Right Grant
- 2000-10-16 UA UA2002054064A patent/UA76095C2/uk unknown
- 2000-10-16 DE DE60023341T patent/DE60023341T2/de not_active Expired - Lifetime
- 2000-10-16 DK DK00975872T patent/DK1237539T3/da active
- 2000-10-16 EP EP00975872A patent/EP1237539B1/en not_active Expired - Lifetime
- 2000-10-16 AU AU13849/01A patent/AU780826C/en not_active Expired
- 2000-10-16 CN CNB008147388A patent/CN1200691C/zh not_active Expired - Lifetime
- 2000-10-16 CZ CZ20021329A patent/CZ301996B6/cs not_active IP Right Cessation
- 2000-10-16 SI SI200030782T patent/SI1237539T1/sl unknown
- 2000-10-16 HU HU0203484A patent/HUP0203484A3/hu unknown
- 2000-10-16 MX MXPA02004149A patent/MXPA02004149A/es active IP Right Grant
- 2000-10-16 WO PCT/EP2000/010203 patent/WO2001030318A1/en active IP Right Grant
- 2000-10-16 CA CA002388830A patent/CA2388830C/en not_active Expired - Lifetime
- 2000-10-16 KR KR10-2002-7003258A patent/KR100502391B1/ko active IP Right Grant
- 2000-10-16 AT AT00975872T patent/ATE306904T1/de active
- 2000-10-16 PL PL362849A patent/PL201694B1/pl unknown
- 2000-10-25 AR ARP000105621A patent/AR026243A1/es not_active Application Discontinuation
-
2002
- 2002-02-28 IS IS6291A patent/IS2628B/is unknown
- 2002-03-20 BG BG106534A patent/BG65792B1/bg unknown
- 2002-04-15 HR HR20020332A patent/HRP20020332B1/xx not_active IP Right Cessation
- 2002-04-24 IL IL149310A patent/IL149310A/en unknown
- 2002-04-25 ZA ZA200203313A patent/ZA200203313B/xx unknown
- 2002-04-26 NO NO20022003A patent/NO332096B1/no not_active IP Right Cessation
-
2003
- 2003-03-10 HK HK03101718A patent/HK1049619A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902056A2 (hu) | Fuzionált 1,2,4-tiadiazin- és fuzionált 1,4-tiazinszármazékok, azok előállítása és alkalmazása | |
| HUP0401344A2 (hu) | Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra | |
| HUP0300030A2 (en) | Bupropion metabolites and methods of their synthesis and use and pharmaceutical compositions containing them and and their use | |
| HUP0401849A2 (hu) | Kinuklidinszármazékok, ezeket tartalmazó gyógyászati készítmények, továbbá ezek alkalmazása M2 és/vagy M3 muszkarin receptor inhibitorként | |
| DE69527842T2 (de) | Oral anzuwendendes flüssiges arzneimittel enthaltend alendronat | |
| HUP0401195A2 (hu) | Averziót okozó szert tartalmazó készítmények opioidokkal való visszaélés megakadályozására | |
| HUP9902105A2 (hu) | Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása | |
| BR9814378A (pt) | Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase | |
| HUP0203325A2 (hu) | Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| NL970006I2 (nl) | Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. | |
| SE0104341D0 (sv) | New use | |
| RU95121731A (ru) | Применение рилузола для лечения нейро-спида и способ получения лекарственного средства | |
| HUP0301447A2 (hu) | Tiotrópium- és salmeterolsókat tartalmazó kombinációs gyógyszerkészítmények | |
| HUP0401201A2 (hu) | Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására | |
| MY135838A (en) | Methods for the treatment of mental disorders | |
| PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
| AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| HUP0203484A2 (hu) | Galantamint és édesítőszert tartalmazó orális oldat és eljárás az előállítására | |
| HUP9903213A1 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease and the medicament itself | |
| HUP0102436A2 (hu) | Reboxetin alkalmazása gyógyszer előállítására idegi rendellenességek ellen | |
| Fawaz | Fatal myeloencephalopathy due to intrathecal vincristine administration | |
| HUP0204391A2 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
| BR9813641A (pt) | "preparados transmucosais de levosimendan" | |
| HUP0200145A2 (hu) | Tianeptin alkalmazása neurodegeneratív betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
| HUP9701606A2 (hu) | Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |